Collegium Pharmaceutical Dividende

Zukünftiges Wachstum Kriterienprüfungen 0/6

Collegium Pharmaceutical hat in der Vergangenheit keine Dividende gezahlt.

Wichtige Informationen

n/a

Dividendenausschüttung

n/a

Ausschüttungsquote

Durchschnittlicher Branchenertrag	2.2%
Nächster Dividendenzahlungstermin	n/a
Ex-Dividendendatum	n/a
Dividende pro Aktie	n/a
Gewinn pro Aktie	US$2.85
Erwartete Dividendenrendite in 3 Jahren	n/a

Aktuelle Dividendenentwicklung

Keine Aktualisierungen

Recent updates

Collegium Pharmaceutical (NASDAQ:COLL) Seems To Use Debt Quite Sensibly

Jun 05

Collegium Pharmaceutical: Some Positives From Its Quarterly 'Miss'

May 13

It Looks Like Shareholders Would Probably Approve Collegium Pharmaceutical, Inc.'s (NASDAQ:COLL) CEO Compensation Package

May 10

Collegium Pharmaceutical Q4: The Beat Goes On

Feb 26

These 4 Measures Indicate That Collegium Pharmaceutical (NASDAQ:COLL) Is Using Debt Reasonably Well

Feb 24

There's No Escaping Collegium Pharmaceutical, Inc.'s (NASDAQ:COLL) Muted Revenues

Jan 05

Here's Why Collegium Pharmaceutical (NASDAQ:COLL) Can Manage Its Debt Responsibly

Nov 12

There Is A Reason Collegium Pharmaceutical, Inc.'s (NASDAQ:COLL) Price Is Undemanding

Feb 15

We Think Collegium Pharmaceutical (NASDAQ:COLL) Can Stay On Top Of Its Debt

Oct 30

Stabilität und Wachstum des Zahlungsverkehrs

Rufe Dividendendaten ab

Stabile Dividende: Es liegen keine ausreichenden Daten vor, um festzustellen, ob die Dividende je Aktie von COLL in der Vergangenheit stabil war.

Wachsende Dividende: Unzureichende Daten, um festzustellen, ob die Dividendenzahlungen von COLL gestiegen sind.

Dividendenrendite im Vergleich zum Markt

Collegium Pharmaceutical Dividendenrendite im Vergleich zum Markt

Wie sieht die Dividendenrendite von COLL im Vergleich zum Markt aus?
Segment	Dividendenrendite
Unternehmen (COLL)	n/a
Untere 25 % des Marktes (US)	1.5%
Markt Top 25 % (US)	4.7%
Branchendurchschnitt (Pharmaceuticals)	2.2%
Analystenprognose in 3 Jahren (COLL)	n/a

Bemerkenswerte Dividende: Es ist nicht möglich, die Dividendenrendite von COLL im Vergleich zu den unteren 25 % der Dividendenzahler zu bewerten, da das Unternehmen keine aktuellen Ausschüttungen gemeldet hat.

Hohe Dividende: Es ist nicht möglich, die Dividendenrendite von COLL im Vergleich zu den besten 25 % der Dividendenzahler zu bewerten, da das Unternehmen keine aktuellen Ausschüttungen gemeldet hat.

Gewinnausschüttung an die Aktionäre

Abdeckung der Erträge: Unzureichende Daten zur Berechnung der Ausschüttungsquote von COLL, um festzustellen, ob die Dividendenzahlungen durch die Gewinne gedeckt sind.

Barausschüttung an die Aktionäre

Cashflow-Deckung: Es ist nicht möglich, die Nachhaltigkeit der Dividende zu berechnen, da COLL keine Ausschüttungen gemeldet hat.

Collegium Pharmaceutical Dividende

Zukünftiges Wachstum Kriterienprüfungen 0/6

Wichtige Informationen

Aktuelle Dividendenentwicklung

Recent updates

Price target increased by 8.6% to US$41.00

Collegium Pharmaceutical (NASDAQ:COLL) Seems To Use Debt Quite Sensibly

New minor risk - Insider selling

Executive VP & Chief Commercial Officer recently sold US$1.1m worth of stock

Executive VP & Chief Commercial Officer notifies of intention to sell stock

Independent Director notifies of intention to sell stock

Collegium Pharmaceutical: Some Positives From Its Quarterly 'Miss'

Collegium Pharmaceutical, Inc. Reaffirms Earnings Guidance for the Full Year 2024

First quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

Collegium Announces CEO Transition

It Looks Like Shareholders Would Probably Approve Collegium Pharmaceutical, Inc.'s (NASDAQ:COLL) CEO Compensation Package

Collegium Pharmaceutical, Inc. to Report Q1, 2024 Results on May 09, 2024

Collegium Pharmaceutical, Inc., Annual General Meeting, May 16, 2024

Investor sentiment improves as stock rises 15%

Executive VP & Chief Commercial Officer notifies of intention to sell stock

Collegium Pharmaceutical Q4: The Beat Goes On

These 4 Measures Indicate That Collegium Pharmaceutical (NASDAQ:COLL) Is Using Debt Reasonably Well

Full year 2023 earnings: EPS exceeds analyst expectations

Collegium Pharmaceutical, Inc. to Report Q4, 2023 Results on Feb 22, 2024

Executive VP & Chief Commercial Officer notifies of intention to sell stock

There's No Escaping Collegium Pharmaceutical, Inc.'s (NASDAQ:COLL) Muted Revenues

Price target increased by 13% to US$37.75

President notifies of intention to sell stock

Executive VP exercised options and sold US$253k worth of stock

Here's Why Collegium Pharmaceutical (NASDAQ:COLL) Can Manage Its Debt Responsibly

Third quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Collegium Pharmaceutical, Inc. Revises Earnings Guidance for the Full-Year of 2023

Collegium Pharmaceutical, Inc. Revises Earnings Guidance for the Full-Year of 2023

New minor risk - Shareholder dilution

Collegium Pharmaceutical, Inc. to Report Q3, 2023 Results on Nov 07, 2023

Collegium Pharmaceutical, Inc. Announces Extension of Nucynta Regulatory Exclusivity Through July 2026

Is Collegium Pharmaceutical (NASDAQ:COLL) Using Too Much Debt?

Second quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Collegium Pharmaceutical, Inc. Reaffirms Earnings Guidance for the Year 2023

Collegium Pharmaceutical, Inc. to Report Q2, 2023 Results on Aug 03, 2023

Price target decreased by 8.3% to US$33.25

Executive VP notifies of intention to sell stock

President notifies of intention to sell stock

Collegium Pharmaceutical, Inc. Reaffirms Product Revenues Guidance for Full-Year 2023

First quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Executive VP & CFO notifies of intention to sell stock

Is Collegium Pharmaceutical (NASDAQ:COLL) A Risky Investment?

Executive VP & Chief Commercial Officer notifies of intention to sell stock

Full year 2022 earnings: EPS misses analyst expectations

Price target increased by 12% to US$36.00

Executive VP notifies of intention to sell stock

Collegium Pharmaceutical, Inc. to Report Q4, 2022 Results on Feb 23, 2023

Price target increased to US$34.00

Collegium Pharmaceutical, Inc. Provides Earnings Guidance for the Year of 2023

Co-Founder & Chairman notifies of intention to sell stock

Appeals Court Affirms Validity of Collegium's Belbuca(R) Patents

Co-Founder & Chairman exercised options and sold US$1.3m worth of stock

President notifies of intention to sell stock

Insufficient new directors

Collegium Pharmaceutical, Inc. Provides Earnings Guidance for the Year of 2022

Third quarter 2022 earnings released: EPS: US$0.013 (vs US$0.23 in 3Q 2021)

Collegium Pharmaceutical, Inc. to Report Q3, 2022 Results on Nov 03, 2022

Is Collegium Pharmaceutical (NASDAQ:COLL) Using Too Much Debt?

Executive VP & CFO notifies of intention to sell stock

Executive VP notifies of intention to sell stock

Second quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Price target increased to US$31.40

Collegium Pharmaceutical, Inc. to Report Q2, 2022 Results on Aug 04, 2022

Consensus forecasts updated

Investor sentiment improved over the past week

Collegium Pharmaceutical (NASDAQ:COLL) Has A Somewhat Strained Balance Sheet

Collegium Pharmaceutical: Oversold And Cheap

Consensus forecasts updated

First quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Insufficient new directors

Collegium Pharmaceutical, Inc. Appoints Neil McFarlane to its Board of Directors

Consensus EPS estimates fall by 16%

Collegium Pharmaceutical, Inc. Provides Revenue Guidance for the Year 2022

Collegium Pharmaceutical, Inc. Announces Master Settlement Agreement Resolving Pending Opioid-Related Litigation

Investor sentiment deteriorated over the past week